GeneriCo says it prevails in IPR of Valeant patent

Generic drug company GeneriCo, LLC said the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office ruled in favor of its petition for Inter Partes Review (IPR) of the Valeant Pharmaceuticals International, Inc. US Patent 8,865,688 (the ‘688 Patent).

“The PTAB’s decision invalidates all of the disputed claims of the ‘688 Patent that previously provided Apriso (extended-release capsules containing 0.375g mesalamine as a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults) FDA Orange Book exclusivity through May 1, 2030,” said GeneriCo.

GeneriCo CEO Daniel Thompson said: “Along with our IPR partner Flat Line Capital, LLC, we are pleased that the PTAB has decided to invalidate all the disputed claims of the ‘688 Patent.

“While more remains to be done, this is a significant step forward to lowering prescription drug costs for patients and healthcare providers in the U.S. system.”